Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

ENTX

Entera Bio Ltd

Jun 14 • 04:00PM ET

2.07

Dollar change -0.01
Percentage change -0.48	%

Healthcare • Biotechnology • Israel • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.29	Insider Own	20.09%	Shs Outstand	35.48M	Perf Week	3.50%
Market Cap	74.15M	Forward P/E	-	EPS next Y	-0.54	Insider Trans	0.91%	Shs Float	28.62M	Perf Month	-20.99%
Income	-8.72M	PEG	-	EPS next Q	-0.06	Inst Own	11.89%	Short Float	0.32%	Perf Quarter	51.09%
Sales	0.00M	P/S	-	EPS this Y	19.35%	Inst Trans	-3.99%	Short Ratio	0.38	Perf Half Y	207.78%
Book/sh	0.25	P/B	8.30	EPS next Y	-116.00%	ROA	-79.80%	Short Interest	0.09M	Perf Year	158.69%
Cash/sh	0.26	P/C	8.01	EPS next 5Y	-	ROE	-92.02%	52W Range	0.52 - 3.35	Perf YTD	245.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	25.05%	ROI	-95.92%	52W High	-38.21%	Beta	1.63
Dividend TTM	-	Quick Ratio	8.70	Sales past 5Y	-23.65%	Gross Margin	-378.57%	52W Low	298.08%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	8.70	EPS Y/Y TTM	28.39%	Oper. Margin	0.00%	RSI (14)	44.29	Volatility	7.01% 7.86%
Employees	37	Debt/Eq	0.04	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	10.00
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	27.76%	Payout	-	Rel Volume	0.18	Prev Close	2.08
Sales Surprise	-	EPS Surprise	183.33%	Sales Q/Q	-	Earnings	May 10 AMC	Avg Volume	242.62K	Price	2.07
SMA20	-7.90%	SMA50	-7.99%	SMA200	69.75%	Trades		Volume	44,646	Change	-0.48%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-22-21	Initiated	Aegis Capital	Buy	$12

Jun-07-24 07:30AM	Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar (InvestorPlace)
Jun-03-24 09:40AM	Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year? (Zacks)
08:00AM	Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024 (GlobeNewswire)
May-23-24 06:45AM	The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom (InvestorPlace)
May-16-24 09:40AM	Are Medical Stocks Lagging Entera Bio (ENTX) This Year? (Zacks)
08:00AM	Loading…
May-15-24 08:00AM	Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member (GlobeNewswire)
May-13-24 07:00AM	Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024 (GlobeNewswire)
May-10-24 08:53PM	ENTX Stock Earnings: Entera Bio Beats EPS for Q1 2024 (InvestorPlace)
04:10PM	Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-26-24 06:00PM	Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
Apr-18-24 06:15PM	Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today (Zacks)
Apr-15-24 03:43PM	Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024? (InvestorPlace) -15.44%
Apr-12-24 09:40AM	Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? (Zacks) +12.03%
Apr-09-24 09:09AM	Here's Why You Should Invest in Entera Bio (ENTX) Stock Now (Zacks) +15.38%
Apr-08-24 08:30AM	Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research (GlobeNewswire)
08:30AM	Loading…
Mar-26-24 08:30AM	Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months (GlobeNewswire)
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Mar-20-24 08:00AM	Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome (GlobeNewswire) +7.79%
Mar-08-24 04:05PM	Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-04-24 08:30AM	Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +19.44%
Jan-30-24 08:30AM	Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-03-24 08:00AM	Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule (GlobeNewswire)
Dec-26-23 08:00AM	Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025 (GlobeNewswire)
Nov-29-23 08:30AM	Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform (GlobeNewswire)
Nov-14-23 07:30AM	Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development (GlobeNewswire)
Nov-09-23 02:30PM	Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis (GlobeNewswire) +20.64%
Oct-16-23 08:00AM	Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting (GlobeNewswire)
Sep-13-23 01:18PM	OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations (Zacks)
Sep-12-23 08:30AM	Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes (GlobeNewswire)
Sep-05-23 08:00AM	Entera Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:30AM	Loading…
Aug-16-23 08:30AM	Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting (GlobeNewswire) +5.02%
Aug-11-23 04:05PM	Entera Bio Announces Q2 2023 Financial Results and Corporate Updates (GlobeNewswire)
Jun-07-23 07:30AM	Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors (GlobeNewswire)
May-07-23 08:10AM	Entera Bio First Quarter 2023 Earnings: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022) (Simply Wall St.)
May-05-23 05:15PM	Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.70%
04:05PM	Entera Bio Announces Q1 2023 Financial Results and Corporate Updates (GlobeNewswire)
May-04-23 10:00AM	Will Entera Bio Ltd. (ENTX) Report Negative Q1 Earnings? What You Should Know (Zacks)
May-03-23 09:34AM	Enteras Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics (GlobeNewswire) +10.00%
Apr-26-23 08:30AM	Menopause Luminary, Dr. Steven R. Goldstein, Joins Enteras Clinical and Scientific Advisory Board (GlobeNewswire)
Apr-03-23 07:00AM	Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program (GlobeNewswire) -13.36%
Mar-31-23 05:15PM	Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:00PM	Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022 (GlobeNewswire)
Mar-23-23 09:27AM	Entera Bio Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Mar-10-23 08:05AM	Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely? (Simply Wall St.)
Feb-20-23 08:34AM	Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-15-23 10:00AM	Entera Bio Announces FDAs Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis (GlobeNewswire) +10.99%
Feb-13-23 09:00AM	Entera Bio to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-10-23 06:00PM	Entera Bio Ltd. (ENTX) Outpaces Stock Market Gains: What You Should Know (Zacks)
Feb-02-23 06:00PM	Entera Bio Ltd. (ENTX) Flat As Market Gains: What You Should Know (Zacks)
Jan-27-23 06:00PM	Entera Bio Ltd. (ENTX) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jan-25-23 06:15PM	Entera Bio Ltd. (ENTX) Flat As Market Sinks: What You Should Know (Zacks)
Jan-18-23 06:15PM	Entera Bio Ltd. (ENTX) Gains As Market Dips: What You Should Know (Zacks)
Nov-16-22 07:27AM	New Strong Buy Stocks for November 16th (Zacks) +15.76%
Nov-10-22 05:45PM	Entera Bio Ltd. (ENTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022 (GlobeNewswire)
Oct-06-22 07:00AM	Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis (GlobeNewswire)
Oct-01-22 08:28AM	Is Entera Bio (NASDAQ:ENTX) In A Good Position To Invest In Growth? (Simply Wall St.)
Sep-21-22 08:30AM	Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613s Potential Impact on Wednesday, September 28th @ 10am ET (GlobeNewswire) +6.61%
Sep-12-22 04:30PM	Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
06:30AM	Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting (GlobeNewswire)
Aug-11-22 06:30AM	Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022 (GlobeNewswire)
Jul-26-22 07:30AM	Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting (GlobeNewswire) +6.82%
Jul-18-22 09:11AM	Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO (Benzinga)
07:05AM	Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position (GlobeNewswire)
Jun-17-22 05:00PM	Entera Bio Announces Departure of Dr. Phillip Schwartz, the Companys President of Research & Development to Pursue Outside Opportunities (GlobeNewswire)
May-16-22 08:00AM	Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy (GlobeNewswire) +9.77%
May-12-22 08:00AM	Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
May-05-22 08:00AM	Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics (GlobeNewswire)
Apr-28-22 08:00AM	Entera Bio to Report First Quarter 2022 Financial Results on May 12 (GlobeNewswire)
Apr-08-22 05:02PM	Recession Fears are Creating a Golden Opportunity for Biotech Stocks (InvestorPlace)
Mar-22-22 08:00AM	Entera Bio to Present at 2022 Maxim Virtual Growth Conference (GlobeNewswire)
Mar-16-22 06:14AM	Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-08-22 06:30AM	Entera Bio Reports Financial Results for the Year Ended December 31, 2021 (GlobeNewswire)
Mar-03-22 09:50AM	Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022 (GlobeNewswire)
Feb-17-22 08:30AM	Entera Bio to Present at Aegis Virtual Conference on February 23rd (GlobeNewswire)
Jan-04-22 08:30AM	Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint (GlobeNewswire)
Nov-10-21 08:30AM	Entera Bio Reports Third Quarter 2021 Financial Results (GlobeNewswire) -5.96%
Oct-28-21 08:30AM	Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs (GlobeNewswire) +5.45%
Oct-06-21 03:47PM	Entera Bio's Formulated Human Parathyroid Hormone Shows Encouraging BMD Data (Benzinga)
08:30AM	Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session (GlobeNewswire)
Sep-17-21 08:09AM	Entera Bio (NASDAQ:ENTX) Is In A Strong Position To Grow Its Business (Simply Wall St.)
Sep-01-21 08:30AM	Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting (GlobeNewswire) +5.74%
Aug-23-21 11:00AM	Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021 (GlobeNewswire)
08:30AM	Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-19-21 09:04AM	New Strong Sell Stocks for August 19th (Zacks) -6.34%
Aug-16-21 06:30AM	Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates (GlobeNewswire) -7.04%
Aug-13-21 04:30PM	Entera Bio to Report Business and Financial Results for the Quarter ended June 30, 2021, on August 16, 2021 (GlobeNewswire)
Aug-06-21 10:20AM	10 Biotech Penny Stocks to Buy According to Reddit (Insider Monkey)
Aug-02-21 08:30AM	Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting (GlobeNewswire)
Jun-28-21 03:15PM	Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis (GlobeNewswire)
Jun-25-21 06:23PM	Entera Bio Stock Could More Than Double From Here, Says Analyst (TipRanks)
Jun-24-21 12:38PM	Entera (ENTX) Up on Positive Results From Osteoporosis Drug (Zacks) -6.00%
03:33AM	Entera Bio Surging on Drug Development; Will the Rise Continue? (TipRanks)
Jun-23-21 08:30AM	Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints (GlobeNewswire) +44.77%
07:39AM	Entera Bio Soars on Phase 2 Progress With Osteoporosis Treatment (TheStreet.com)
Jun-19-21 05:12AM	Are Institutions Heavily Invested In Entera Bio Ltd.'s (NASDAQ:ENTX) Shares? (Simply Wall St.)
Jun-18-21 06:22AM	Entera Bio (ENTX) is Overbought: Is A Drop Coming? (Zacks) -14.84%
Jun-17-21 08:00AM	Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union (GlobeNewswire) +24.76%
May-20-21 08:00AM	Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates (GlobeNewswire)
May-19-21 08:47AM	Here's Why Entera Bio (ENTX) Stock Has Almost Tripled This Year (Zacks) -5.66%

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Taitel Haya	Director	Jan 12 '24	Buy	0.99	9,500	9,405	35,115	Jan 16 08:00 AM
Taitel Haya	Director	Jan 10 '24	Buy	0.77	7,615	5,864	25,615	Jan 11 06:14 PM
LIEBERMAN GERALD M	Director	Dec 22 '23	Buy	0.71	23,952	17,006	226,961	Dec 27 05:00 PM
Toledano Miranda Jayne	Chief Executive Officer	Dec 22 '23	Buy	0.71	23,952	17,006	110,752	Dec 27 08:27 AM
Taitel Haya	Director	Aug 22 '23	Buy	0.62	18,000	11,216	18,000	Aug 24 08:12 AM
Ellis Sean	Director	Aug 21 '23	Buy	0.60	40,000	24,000	102,100	Aug 22 09:20 AM
LIEBERMAN GERALD M	Director	Aug 21 '23	Buy	0.59	20,000	11,784	214,209	Aug 23 09:28 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENTX

Entera Bio Ltd

Upgrade your FINVIZ experience